Westlake Genetech (Hangzhou) Co., Ltd. is an innovative biotech company, a start-up from scientific research achievements of Westlake University. We focus on the rapid development of first-in-class drugs by integrating the 3H (high throughput, high precision, high dimension) biotechnological data production and deep learning modeling.By building technology-driven gene therapy technology platforms and developing differentiated self-developed gene therapy products, we are committed to mapping the full-process implementation of AI-powered gene therapy.

GOAL

We have built an interdisciplinary team covering genomics, deep learning, bioinformatics, molecular biology, cell biology, and immunology, with more than 50 full-time employees, of which more than 60% are doctors and masters. We provide first-class supporting facilities for the team's research and development work, with a total area of nearly 2,600 ㎡ for early R&D lab and office. At the same time, we have actively cooperated with research institutes, especially Westlake University. In addition, we have built a high-standard GMP facility of 1,149 ㎡, which can be used to promote the clinical transformation of research and development products and produce gene-modified cell therapy products that meet the standards of NHC and NMPA.

SUPPORT

Westlake Genetech adheres to the development strategy of "platform + pipeline" dual-wheel drive, actively invests in R&D innovation that combines technological leadership and industrial feasibility, and promotes the technological and commercial landing of AI technology in the vertical field of biomedicine. Our self-developed AI-powered full-chain gene therapy technology platform has evolved to generate a large number of non-liver-targeted AAV capsids, developed gene editing tools with independent intellectual property rights, explored new targets, and developed safe, efficient, and accessible gene therapy innovative therapies for rare diseases, tumors, and other diseases. With the platform's empowerment, it will effectively expand the scope of gene therapy indications, significantly shorten the pipeline development time, improve the pipeline R&D efficiency, and achieve the optimization of cost reduction and efficiency improvement and technology tool selection. We are rapidly advancing our technological achievements to the field of disease treatment, laying out ex vivo and in vivo gene therapy, developing differentiated gene therapy products, and solving more unmet clinical needs.

HIGHLIGHT